id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0036,FDA,FDA-2012-D-0880,Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Draft Guidance for Industry; Final Guidance,Other,Guidance,2023-06-08T04:00:00Z,2023,6,2023-06-08T04:00:00Z,,2024-11-11T21:23:32Z,,1,0,0900006485ae0c44
FDA-2012-D-0880-0035,FDA,FDA-2012-D-0880,Final Guidance for Industry - Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2024-11-07T00:38:54Z,,1,0,09000064850894ca
FDA-2012-D-0880-0034,FDA,FDA-2012-D-0880,Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Guidance for Industry; Availability,Notice,Notice of Availability,2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2022-05-18T19:49:37Z,2022-10702,0,0,090000648508897a
FDA-2012-D-0880-0030,FDA,FDA-2012-D-0880,Draft Guidance for Industry - Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2024-11-12T23:11:37Z,,1,0,09000064841152bd
FDA-2012-D-0880-0029,FDA,FDA-2012-D-0880,"Assessing User Fees Under the Generic Drug User Fee Amendments of
2017; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,2020-01-01T04:59:59Z,2019-12-21T02:01:25Z,2019-23875,0,0,0900006484113ec1
FDA-2012-D-0880-0024,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Assessing User Fees Under the Generic Drug User Fee Amendments of 2017,Other,Guidance,2017-10-30T04:00:00Z,2017,10,2017-10-30T04:00:00Z,,2022-05-19T15:23:06Z,,0,0,0900006482c22925
FDA-2012-D-0880-0023,FDA,FDA-2012-D-0880,"Assessing User Fees Under the Generic Drug User Fee Amendments of 
2017; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-10-30T04:00:00Z,2017,10,2017-10-30T04:00:00Z,2017-12-30T04:59:59Z,2017-12-29T02:00:42Z,2017-23526,0,0,0900006482c21d18
FDA-2012-D-0880-0021,FDA,FDA-2012-D-0880,"Generic Drug User Fee Amendments of 2012: Questions and Answers Related to Self-Identification of Facilities, Review of Generic Drug Submissions, and Inspections and Compliance; Guidance for Industry; Availability",Notice,Notice of Availability,2017-07-26T04:00:00Z,2017,7,2017-07-26T04:00:00Z,,2017-07-26T13:59:13Z,2017-15654,0,0,090000648296a012
FDA-2012-D-0880-0022,FDA,FDA-2012-D-0880,Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments Guidance for Industry,Other,Guidance,2017-07-26T04:00:00Z,2017,7,2017-07-26T04:00:00Z,,2024-11-07T01:03:50Z,,1,0,090000648296d644
FDA-2012-D-0880-0020,FDA,FDA-2012-D-0880,Final Guidance for Industry Generic Drug User Fee Amendments of 2012 - Questions and Answers Related t User Fee Assessments,Other,Guidance,2016-12-14T05:00:00Z,2016,12,2016-12-14T05:00:00Z,,2024-11-07T23:53:21Z,,1,0,0900006482409ef4
FDA-2012-D-0880-0018,FDA,FDA-2012-D-0880,Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments; Guidance for Industry; Availability,Notice,Notice of Availability,2016-11-18T05:00:00Z,2016,11,2016-11-18T05:00:00Z,,2016-11-18T17:35:39Z,2016-27761,0,0,09000064823a05f3
FDA-2012-D-0880-0019,FDA,FDA-2012-D-0880,Draft Guidance for Generic Drug User Fee Amendments of 2012 Questions and Answers,Other,Guidance,2016-11-18T05:00:00Z,2016,11,2016-11-18T05:00:00Z,,2024-11-12T06:16:24Z,,1,0,09000064823a0ef6
FDA-2012-D-0880-0009,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1); Reopening of the Comment Period,Notice,General Notice,2013-11-27T05:00:00Z,2013,11,2013-11-27T05:00:00Z,2013-12-12T04:59:59Z,2016-11-18T14:46:02Z,2013-28392,0,0,090000648149c2b6
FDA-2012-D-0880-0006,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1); Availability,Notice,Notice of Availability,2013-09-10T04:00:00Z,2013,9,2013-09-10T04:00:00Z,2013-11-27T04:59:59Z,2016-11-18T14:44:33Z,2013-21891,0,0,09000064813ebe4c
FDA-2012-D-0880-0007,FDA,FDA-2012-D-0880,Draft Guidance for Industry on Generic Drug User Fee Amendments of 2012: Questions and Answers (Revision 1),Other,Guidance,2013-09-10T04:00:00Z,2013,9,2013-09-10T04:00:00Z,,2024-11-07T22:57:45Z,,1,0,09000064813eca54
FDA-2012-D-0880-0001,FDA,FDA-2012-D-0880,"Draft Guidances for Industry: Generic Drug User Fee Amendments of 2012, Questions and Answers",Notice,Notice of Availability,2012-08-27T04:00:00Z,2012,8,2012-08-27T04:00:00Z,2012-10-27T03:59:59Z,2012-10-02T02:01:15Z,2012-20944,0,0,09000064810f2477
FDA-2012-D-0880-0002,FDA,FDA-2012-D-0880,"Draft Guidances for Industry: Generic Drug User Fee Amendments of 2012, Questions and Answers",Other,Guidance,2012-08-27T04:00:00Z,2012,8,2012-08-27T04:00:00Z,,2024-11-12T04:51:37Z,,1,0,09000064810f272a